Drug approvals to watch in 2026

Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for hospital formularies, prescribing protocols and patient access. A report published Jan. 8 by GoodRx, “FDA Approval Watch: New Drugs, Vaccines, and Therapies Pending Approval in 2026” outlines several […]

VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug

Viking Therapeutics VKTX announced that it has completed enrolling patients in its exploratory maintenance dosing study of VK2735, the company’s dual agonist of the GLP-1 and GIP receptors. VKTX is developing the candidate in both oral and subcutaneous (SC) formulations for the potential treatment of various metabolic disorders, such as obesity. Viking Therapeutics’ phase I maintenance […]

Here’s Why Biotech ETFs Are Rallying Hard

Biotech stocks have rallied strongly into 2026, building on the late-2025 momentum from positive clinical data, cheaper valuation, easy money policy and favorable macro conditions. Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB rallied 36.7% in six months ending Jan. 7, 2026, outperforming SPDR S&P 500 ETF Trust SPY (up 11.2%). Year to date, IBB has risen 4.2% compared […]

The Simply Good Foods Company (NASDAQ:SMPL) Q1 2026 Earnings Call Transcript

The Simply Good Foods Company (NASDAQ:SMPL) Q1 2026 Earnings Call Transcript January 8, 2026 The Simply Good Foods Company beats earnings expectations. Reported EPS is $0.39, expectations were $0.36. Operator: Greetings. Welcome to Simply Good Foods Company’s First Quarter Fiscal Year 2026 Earnings Call. [Operator Instructions] Please note, this conference is being recorded. At this […]